Thrombotic thrombocytopenic purpura and simvastatin

Eight-year outcomes of testosterone suppression plus enzalutamide or a non-steroidal anti-androgen for metastatic, hormone-sensitive prostate cancer (ENZAMET; ANZUP 1304).

Annals of oncology : official journal of the European Society for Medical Oncology·2026

Multimodal artificial intelligence prediction of abiraterone efficacy in two STAMPEDE phase III trials of nonmetastatic very high-risk prostate cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2026

Ten-year survival rates by PSA nadir in patients with metastatic hormone-sensitive prostate cancer: long-term survival analysis from the ECOG-ACRIN 3805 (CHAARTED) trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2025

Association of the circulating lipid panel, PCPro, with clinical outcomes in metastatic hormone-sensitive prostate cancer: post hoc analysis of the ENZAMET phase III randomised trial (ANZUP 1304).

Annals of oncology : official journal of the European Society for Medical Oncology·2025

Validation of metastasis-free survival as a surrogate endpoint for overall survival in localized prostate cancer in the era of docetaxel for castration-resistant prostate cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2023

Next generation radiotheranostics promoting precision medicine.

Annals of oncology : official journal of the European Society for Medical Oncology·2023

Rezpegaldesleukin treatment of moderate-to-severe atopic dermatitis (REZOLVE-AD): final results from the 16-week induction period of an international, double-blind, placebo-controlled, randomised phase 2b study.

Lancet (London, England)·2026

Robotic-arm-assisted versus conventional total knee replacement (RACER-Knee): a pragmatic, multicentre, participant-masked and assessor-masked, superiority, randomised controlled trial.

Lancet (London, England)·2026

Risk of transmission of amyloid β pathology via transfused blood products.

Lancet (London, England)·2026

Liver resection after atezolizumab and bevacizumab versus maintenance therapy for locally advanced hepatocellular carcinoma (TALENTOP): a multicentre, open-label, randomised, phase 3 trial.

Lancet (London, England)·2026

Risk factors for poor prognosis in patients with acute ischaemic stroke: a retrospective study.

Acta cardiologica·2026

A Phase IIa, Double Blind, Randomized, Placebo Controlled, Parallel, Multicentre, Proof-of-Concept Study to Evaluate the Efficacy and Safety of Desidustat Oral Tablet for Treatment of Sickle Cell Disease.

European journal of haematology·2026

Associations of hereditary angioedema attacks with intestinal permeability and inflammatory cytokines.

Frontiers in immunology·2026

Development and Validation of a Nomogram Based on Red Blood Cell and Reticulocyte Parameters for Differentiating Thalassemia Trait From Iron Deficiency Anemia.

Journal of clinical laboratory analysis·2026

Primary Anastomosis Versus Hartmann's Procedure in Acute Care Surgery: Evidence, Indications, and Barriers to Adoption.

The American surgeon·2026

Related Experiment Videos

Thrombotic thrombocytopenic purpura and simvastatin

Related Concept Videos

Eight-year outcomes of testosterone suppression plus enzalutamide or a non-steroidal anti-androgen for metastatic, hormone-sensitive prostate cancer (ENZAMET; ANZUP 1304).

Multimodal artificial intelligence prediction of abiraterone efficacy in two STAMPEDE phase III trials of nonmetastatic very high-risk prostate cancer.

Ten-year survival rates by PSA nadir in patients with metastatic hormone-sensitive prostate cancer: long-term survival analysis from the ECOG-ACRIN 3805 (CHAARTED) trial.

Association of the circulating lipid panel, PCPro, with clinical outcomes in metastatic hormone-sensitive prostate cancer: post hoc analysis of the ENZAMET phase III randomised trial (ANZUP 1304).

Validation of metastasis-free survival as a surrogate endpoint for overall survival in localized prostate cancer in the era of docetaxel for castration-resistant prostate cancer.

Next generation radiotheranostics promoting precision medicine.

Rezpegaldesleukin treatment of moderate-to-severe atopic dermatitis (REZOLVE-AD): final results from the 16-week induction period of an international, double-blind, placebo-controlled, randomised phase 2b study.

Robotic-arm-assisted versus conventional total knee replacement (RACER-Knee): a pragmatic, multicentre, participant-masked and assessor-masked, superiority, randomised controlled trial.

Risk of transmission of amyloid β pathology via transfused blood products.

Liver resection after atezolizumab and bevacizumab versus maintenance therapy for locally advanced hepatocellular carcinoma (TALENTOP): a multicentre, open-label, randomised, phase 3 trial.

Risk factors for poor prognosis in patients with acute ischaemic stroke: a retrospective study.

A Phase IIa, Double Blind, Randomized, Placebo Controlled, Parallel, Multicentre, Proof-of-Concept Study to Evaluate the Efficacy and Safety of Desidustat Oral Tablet for Treatment of Sickle Cell Disease.

Associations of hereditary angioedema attacks with intestinal permeability and inflammatory cytokines.

Development and Validation of a Nomogram Based on Red Blood Cell and Reticulocyte Parameters for Differentiating Thalassemia Trait From Iron Deficiency Anemia.

Primary Anastomosis Versus Hartmann's Procedure in Acute Care Surgery: Evidence, Indications, and Barriers to Adoption.

Related Experiment Videos

Thrombotic thrombocytopenic purpura and simvastatin

Related Concept Videos

Related Articles